112
Participants
Start Date
December 31, 2007
Primary Completion Date
April 30, 2008
Study Completion Date
May 31, 2008
ACT-078573 oral capsules at 25 and 100 mg and matching placebo
5-period, 5-treatment crossover: sequences: ABECD, BCADE, CDBEA, DECAB, EADBC DCEBA, EDACB, AEBDC, BACED, CBDAE Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
ACT-078573 and matching placebo
ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
ACT-078573 and matching placebo
ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
ACT-078573 and matching placebo
ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
ACT-078573 and matching placebo
ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
ACT-078573 and matching placebo
ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
ACT-078573 and matching placebo
ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
ACT-078573 and matching placebo
ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
ACT-078573 and matching placebo
ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
ACT-078573 and matching placebo
ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
Duke University, Durham
Sleep Disorders Center, Columbia
Neurotrials Research, Inc., Atlanta
Sleep Disorders Center of Georgia, Atlanta
Broward Research Group & Sleep-Wake Disorders Center of South Florida, Pembroke Pines
Miami Research Associates, Miami
PAB Clinical Research, Brandon
OmniTrials, Naples
Community Research, Crestview Hills
Cleveland Clinic Health Systems, Cleveland
Tri-State Sleep Disorders Center, Cincinnati
Clinical Neurophysiology Services, P.C., Troy
Sleep Disorders & Research Center, Chesterfield
Vince and Associates Clinical Research, Overland Park
Central Arkansas Research, Hot Springs
Lynn Health Sciences Institute, Oklahoma City
Sleep Medicine Associates P.A., Dallas
Clinical Research Center of Nevada, Las Vegas
Pacific Sleep Medicine Services, Inc., Los Angeles
Pacific Sleep Medicine Services, Inc., San Diego
California Clinical Trials Medical Group, Inc., San Diego
Lead Sponsor
Midnight Pharma, LLC
INDUSTRY